For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Catalyst Biosciences, Inc.

USPTO Granted Patents = 26

% Expired Patents = 26.9

CIPO Patents = 8

EPO Patents = 17

Forward Citations = 242

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

Edwin L Madison (16 out of 36 patents)

Christopher D Thanos (10 out of 60 patents)

Sandra Waugh Ruggles (4 out of 11 patents)

4. Jack Nguyen (4 out of 4 patents)

5. Vanessa Soros (3 out of 9 patents)

6. Mikhail Popkov (3 out of 11 patents)

7. Grant Ellsworth Blouse (3 out of 3 patents)

8. Howard Levy (2 out of 2 patents)

9. Srinivasa Rao Akireddy (2 out of 14 patents)

10. Balwinder Singh Bhatti (2 out of 43 patents)

11. Daniel Yohannes (2 out of 10 patents)

12. Matt S Melvin (2 out of 6 patents)

13. Yunde Xiao (2 out of 8 patents)

14. Charles S Craik (2 out of 22 patents)

15. Ronald Joseph Heemstra (2 out of 5 patents)

Core Competencies:

Factor IX Polypeptides

Factor VII Polypeptides

Modified Proteases

Hemophilia Treatment

Nicotinic Receptor Antagonists

MT-SP1 Proteases

Protease Screening

Nucleic Acid Encoding

26 patents: Sort by Forward Citations

1. 11491212 - Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B (2022-11-08),

2. 11401513 - Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use (2022-08-02),

3. 11266724 - Modified factor VII polypeptides for subcutaneous administration and on-demand treatment (2022-03-08),

4. 11203749 - Factor VII polypeptides that are modified and uses thereof (2021-12-21),

5. 10982203 - Modified factor IX polypeptides and uses thereof (2021-04-20),

6. 10954501 - Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use (2021-03-23),

7. 10781435 - Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use (2020-09-22),

8. 10716770 - Nicotinic receptor non-competitive antagonists (2020-07-21),

9. 10258582 - Nicotinic receptor non-competitive antagonists (2019-04-16),

10. 10160961 - Factor VII polypeptides that are modified and uses thereof (2018-12-25),

11. 9856467 - Modified factor X polypeptides and uses thereof (2018-01-02),

12. 9795655 - Modified MT-SP1 proteases that inhibit complement activation (2017-10-24),

13. 9476037 - Factor VII polypeptides that are modified and uses thereof (2016-10-25),

14. 9359598 - Mutant MT-SP1 proteases with altered substrate specificity or activity (2016-06-07),

15. 9328339 - Modified factor IX polypeptides and uses thereof (2016-05-03),

Company Overview

Catalyst Biosciences, Inc. is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for rare and serious diseases. The company specializes in the design and engineering of proteases, which are enzymes that play a critical role in various biological processes. Catalyst's research primarily targets conditions related to hematology and other therapeutic areas, leveraging advanced protein engineering techniques to create novel treatment options aimed at improving patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

26 Patents

#50 in South San Francisco, CA

#3,041 in California

#12,859 in US

#24,806 in the World

South San Francisco, CA, United States of America

Catalyst Biosciences, Inc.

Forward Citations = 242

26 inventors:

Edwin L Madison (16 out of 36 patents)

Christopher D Thanos (10 out of 60 patents)

Sandra Waugh Ruggles (4 out of 11 patents)

4. Jack Nguyen (4 out of 4 patents)

5. Vanessa Soros (3 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Catalyst Biosciences, Inc.. Retrieved from https://idiyas.com/company/catalyst-biosciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…